5. Progressive supranuclear palsy Clinical trials / Disease details


Clinical trials : 95 Drugs : 119 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-007520-26-DE
(EUCTR)
24/06/201013/11/2009A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III) Progressive Supranuclear Palsy
MedDRA version: 12.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy
Trade Name: Azilect
INN or Proposed INN: Rasagilin
Other descriptive name: RASAGILINE MESILATE
Klinikum der Universität MünchenNULLNot RecruitingFemale: yes
Male: yes
Phase 3Germany
2NCT01187888
(ClinicalTrials.gov)
January 201020/8/2010Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III)Progressive Supranuclear PalsyDrug: Rasagiline;Drug: Sugar pillProf. Dr. Stefan LorenzlTeva Pharmaceutical Industries;Ludwig-Maximilians - University of MunichTerminated50 Years80 YearsBoth44Phase 3Germany